This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

End-payors for Amitiza seek class certification in US antitrust case against Takeda (corrects*)

( October 23, 2024, 15:37 GMT | Official Statement) -- MLex Summary: End-payors for the drug Amitiza* asked a US federal judge to certify a proposed class in litigation accusing Takeda Pharmaceuticals of delaying a generic competitor. If approved, the class would consist of anyone who indirectly purchased Amitiza from Takeda in 23 states and the District of Columbia during various class periods. *Corrected on Feb. 7, 2025 at 17:08 GMT: The name of the drug was misspelled in the original. See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections